A Predictive Nomogram for Early Death in Pheochromocytoma and Paraganglioma.
SEER (surveillance epidemiology and end results) database
early death
nomogram
paraganglioma
pheochromocytoma
survival analysis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
09
2021
accepted:
14
01
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Pheochromocytoma (PHEO) and paraganglioma (PGL) are relatively rare neuroendocrine tumors. The factors affecting patients with early death remain poorly defined. We aimed to study the demographic and clinicopathologic pattern and to develop and validate a prediction model for PHEO/PGL patients with early death. Data of 800 participants were collected from the Surveillance Epidemiology and End Results (SEER) database as a construction cohort, while data of 340 participants were selected as a validation cohort. Risk factors considered included the year of diagnosis, age at diagnosis, gender, marital status, race, insurance status, tumor type, primary location, laterality, the presence of distant metastasis. Univariate and multivariate logistic regressions were performed to determine the risk factors. R software was used to generate the nomogram. Calibration ability, discrimination ability, and decision curve analysis were analyzed in both construction and validation cohorts. PHEO and PGL patients accounted for 54.3% (N=434) and 45.7% (N=366), respectively. More than half of tumors (N=401, 50.1%) occurred in the adrenal gland, while 16.9% (N=135) were in aortic/carotid bodies. For the entire cohort, the median overall survival (OS) was 116.0 (95% CI: 101.5-130.5) months. The multivariate analysis revealed that older age ( We developed and validated a predictive nomogram utilizing data from the SEER database with satisfactory discrimination and calibration capability which can be used for early death prediction for PHEO/PGL patients.
Sections du résumé
Background
UNASSIGNED
Pheochromocytoma (PHEO) and paraganglioma (PGL) are relatively rare neuroendocrine tumors. The factors affecting patients with early death remain poorly defined. We aimed to study the demographic and clinicopathologic pattern and to develop and validate a prediction model for PHEO/PGL patients with early death.
Methods
UNASSIGNED
Data of 800 participants were collected from the Surveillance Epidemiology and End Results (SEER) database as a construction cohort, while data of 340 participants were selected as a validation cohort. Risk factors considered included the year of diagnosis, age at diagnosis, gender, marital status, race, insurance status, tumor type, primary location, laterality, the presence of distant metastasis. Univariate and multivariate logistic regressions were performed to determine the risk factors. R software was used to generate the nomogram. Calibration ability, discrimination ability, and decision curve analysis were analyzed in both construction and validation cohorts.
Results
UNASSIGNED
PHEO and PGL patients accounted for 54.3% (N=434) and 45.7% (N=366), respectively. More than half of tumors (N=401, 50.1%) occurred in the adrenal gland, while 16.9% (N=135) were in aortic/carotid bodies. For the entire cohort, the median overall survival (OS) was 116.0 (95% CI: 101.5-130.5) months. The multivariate analysis revealed that older age (
Conclusions
UNASSIGNED
We developed and validated a predictive nomogram utilizing data from the SEER database with satisfactory discrimination and calibration capability which can be used for early death prediction for PHEO/PGL patients.
Identifiants
pubmed: 35280784
doi: 10.3389/fonc.2022.770958
pmc: PMC8913719
doi:
Types de publication
Journal Article
Langues
eng
Pagination
770958Informations de copyright
Copyright © 2022 Li, Abbas, Abdelazeem, Xu, Lin, Wu, Chekhonin, Peltzer and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Otolaryngol. 2013 Sep-Oct;34(5):431-8
pubmed: 23642313
J Clin Endocrinol Metab. 2011 Mar;96(3):717-25
pubmed: 21190975
J Clin Endocrinol Metab. 2002 Sep;87(9):4101-5
pubmed: 12213855
Int J Colorectal Dis. 2019 Jul;34(7):1189-1201
pubmed: 31089875
Surg Oncol Clin N Am. 2016 Jan;25(1):119-38
pubmed: 26610778
BJU Int. 2010 Aug;106(3):342-8
pubmed: 20002664
Med Sci Monit. 2020 Aug 11;26:e924858
pubmed: 32778637
Endocr Relat Cancer. 2004 Sep;11(3):423-36
pubmed: 15369446
Cancer. 2002 Feb 1;94(3):730-7
pubmed: 11857306
Endocrinol Metab Clin North Am. 2019 Dec;48(4):727-750
pubmed: 31655773
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3296-3305
pubmed: 28605453
Skull Base. 2011 Nov;21(6):385-8
pubmed: 22547965
Issue Brief (Commonw Fund). 2016 Aug;27:1-12
pubmed: 27571600
Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):905-912
pubmed: 30419307
J Cancer. 2020 Jul 9;11(18):5359-5370
pubmed: 32742482
Endocr Pathol. 2017 Sep;28(3):213-227
pubmed: 28477311
Pancreas. 2010 Aug;39(6):775-83
pubmed: 20664475
Ann Surg Oncol. 2020 May;27(5):1329-1337
pubmed: 32112212
J Surg Oncol. 2013 May;107(6):659-64
pubmed: 23233320
Head Neck Oncol. 2010 Sep 23;2:23
pubmed: 20863367
Nat Rev Endocrinol. 2015 Feb;11(2):101-11
pubmed: 25385035
Sisli Etfal Hastan Tip Bul. 2020 Jun 03;54(2):159-168
pubmed: 32617052
J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
pubmed: 24893135
Horm Metab Res. 2019 Jul;51(7):451-457
pubmed: 30919391
Endocr Rev. 2017 Dec 1;38(6):489-515
pubmed: 28938417
J Endocrinol Invest. 2022 Jan;45(1):149-157
pubmed: 34227051